Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Sees Large Volume Increase – Still a Buy?

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) shares saw unusually-strong trading volume on Tuesday. Approximately 870,298 shares traded hands during trading, an increase of 15% from the average daily volume of 755,991 shares. The stock last traded at $21.6350 and had previously closed at $22.61.

Analyst Ratings Changes

FMS has been the subject of a number of research reports. Citigroup reiterated a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Friday, July 17th. BNP Paribas Exane lowered Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating and set a $19.90 price objective for the company. in a report on Tuesday, July 28th. Truist Financial reduced their price objective on shares of Fresenius Medical Care AG & Co. KGaA from $25.00 to $24.00 and set a “hold” rating for the company in a research report on Monday, October 12th. Weiss Ratings upgraded Fresenius Medical Care AG & Co. KGaA from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Finally, Zacks Research downgraded Fresenius Medical Care AG & Co. KGaA from a “hold” rating to a “strong sell” rating in a research report on Thursday, October 15th. Seven investment analysts have rated the stock with a Hold rating and four have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average target price of $23.42.

Fresenius Medical Care AG & Co. KGaA Trading Up 2.0%

The stock has a market cap of $12.58 billion, a PE ratio of 13.67, a PEG ratio of 5.07 and a beta of 0.78. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The firm has a fifty day simple moving average of $22.33 and a two-hundred day simple moving average of $22.89.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last announced its quarterly earnings data on Monday, August 3rd. The company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.62 by $0.04. Fresenius Medical Care AG & Co. KGaA had a return on equity of 9.03% and a net margin of 4.23%. The firm had revenue of $5.55 billion for the quarter, compared to analyst estimates of $5.48 billion. As a group, equities analysts expect that Fresenius Medical Care AG & Co. KGaA will post 2.24 earnings per share for the current fiscal year.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

Several large investors have recently modified their holdings of FMS. Mather Group LLC. increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 838.0% during the third quarter. Mather Group LLC. now owns 1,407 shares of the company’s stock valued at $31,000 after buying an additional 1,257 shares during the period. Farther Finance Advisors LLC grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 39.1% in the third quarter. Farther Finance Advisors LLC now owns 1,915 shares of the company’s stock worth $43,000 after acquiring an additional 538 shares during the last quarter. Allworth Financial LP increased its stake in Fresenius Medical Care AG & Co. KGaA by 31.5% during the 2nd quarter. Allworth Financial LP now owns 3,552 shares of the company’s stock valued at $80,000 after purchasing an additional 850 shares in the last quarter. Integrated Wealth Concepts LLC bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA during the second quarter valued at approximately $91,000. Finally, EverSource Wealth Advisors LLC raised its stake in shares of Fresenius Medical Care AG & Co. KGaA by 50.3% in the first quarter. EverSource Wealth Advisors LLC now owns 4,135 shares of the company’s stock worth $93,000 after purchasing an additional 1,383 shares during the last quarter. 8.37% of the stock is owned by institutional investors.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is a Germany-based health care company focused on the treatment of chronic kidney failure. The company provides dialysis care for patients with end-stage renal disease through a network of outpatient dialysis clinics and other health care facilities.

In addition to operating dialysis centers, Fresenius Medical Care develops and supplies products used in dialysis treatment. Its portfolio includes hemodialysis machines, dialyzers, dialysis solutions, bloodlines, and related medical devices and services.